Lynce F, Williams JT, Regan MM, Bunnell CA, et al. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 2021 Feb 14. pii: 10.1007/s00280-021-04245.
PMID: 33585999